Copyright
©The Author(s) 2022.
World J Psychiatry. Mar 19, 2022; 12(3): 410-424
Published online Mar 19, 2022. doi: 10.5498/wjp.v12.i3.410
Published online Mar 19, 2022. doi: 10.5498/wjp.v12.i3.410
Figure 6 Magnesium-L-threonate treatment prevented the upregulation of amyloid β1-42, hypoxia-inducible factor-1α and NADPH oxidase 4 proteins in APPswe/PS1dE9 mouse hippocampus.
A: Protein band images of hypoxia-inducible factor (HIF)-1α, NADPH oxidase (NOX) 4, amyloid β (Aβ)1-42 and glyceraldehyde-3-phosphate dehydrogenase of each group; B: The HIF-1α protein expression of each group; C: The NOX4 protein expression of each group; D: The Aβ1-42 protein expression of each group. n = 3. aP < 0.05, bP < 0.01, cP < 0.001 vs former group. MgT: Magnesium-L-threonate; TG: APPswe/PS1dE9 mice group; WT: Wild-type mice group; Aβ: Amyloid β; HIF: hypoxia-inducible factor; NOX: NADPH oxidase; GAPDH: glyceraldehyde-3-phosphate dehydrogenase.
- Citation: Xiong Y, Ruan YT, Zhao J, Yang YW, Chen LP, Mai YR, Yu Q, Cao ZY, Liu FF, Liao W, Liu J. Magnesium-L-threonate exhibited a neuroprotective effect against oxidative stress damage in HT22 cells and Alzheimer’s disease mouse model. World J Psychiatry 2022; 12(3): 410-424
- URL: https://www.wjgnet.com/2220-3206/full/v12/i3/410.htm
- DOI: https://dx.doi.org/10.5498/wjp.v12.i3.410